GO:0006198 cAMP catabolic process: Degradation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006198 (cAMP catabolic process) describes the biochemical breakdown of cyclic AMP (cAMP), a universal second messenger.
• Phosphodiesterases (PDEs) are the principal enzymes that hydrolyze cAMP to 5'-AMP, thereby terminating cAMP signaling.
• cAMP catabolism is spatially compartmentalized, with PDEs shaping local cAMP nanodomains in cells such as cardiomyocytes and astrocytes.
• Dysregulated cAMP breakdown contributes to diseases including thyroid carcinoma, cardiovascular disorders, and neurological conditions.
• CRISPR-based knockout, point mutation, and knock-in models enable precise interrogation of PDE and cAMP pathway genes.
• Advanced methods such as live-cell cAMP imaging, phosphoproteomics, and CRISPR library screening are essential for studying cAMP catabolism.
Description
The Gene Ontology term GO:0006198, cAMP catabolic process, defines the set of biochemical reactions that degrade cyclic AMP (cAMP) into its breakdown product, 5'-AMP. cAMP is a pivotal second messenger that transduces signals from G protein-coupled receptors to downstream effectors such as protein kinase A (PKA) and exchange proteins directly activated by cAMP (EPAC). The intensity and duration of cAMP signaling are tightly controlled not only by synthesis via adenylyl cyclases but also by degradation through phosphodiesterases (PDEs). This catabolic process is therefore central to cellular homeostasis and signal fidelity. Researchers study cAMP catabolism because it shapes the amplitude, duration, and spatial distribution of cAMP signals within cells. In the heart, for example, localized cAMP nanodomains are sculpted by specific PDEs, and their disruption can lead to arrhythmias and heart failure. In the brain, astroglial cAMP signaling is dynamically regulated by PDE activity, influencing neuronal excitability and synaptic plasticity. Moreover, altered cAMP catabolism has been implicated in cancer, metabolic disorders, and mitochondrial dysfunction. Understanding GO:0006198 thus provides a mechanistic framework for dissecting how cells turn off cAMP signals, and it offers a rich source of therapeutic targets. This article integrates authoritative GO annotations with published literature to outline the definition, molecular players, disease relevance, and experimental strategies for studying cAMP catabolic process.
cAMP catabolic process At A Glance
| GO ID | GO:0006198 |
|---|---|
| GO term | cAMP catabolic process |
| Ontology | biological_process |
| Synonym | cAMP breakdown; cAMP degradation; cyclic AMP catabolic process; 3',5'-cAMP catabolism |
| Major function | Termination of cAMP signaling by hydrolyzing cAMP to 5'-AMP |
| Key enzymes | Phosphodiesterases (PDE1, PDE2, PDE3, PDE4, PDE7, PDE8, PDE10, PDE11) |
| Subcellular location | Cytosol, plasma membrane, nucleus, mitochondria, and other compartments |
| Pathway context | cAMP signaling; GPCR signal termination; purine nucleotide catabolism |
What Is GO:0006198?
According to the Gene Ontology, GO:0006198 cAMP catabolic process is defined as the chemical reactions and pathways resulting in the breakdown of the nucleotide cAMP (cyclic AMP, adenosine 3',5'-cyclophosphate). In essence, it encompasses all enzymatic and spontaneous processes that convert cAMP into degradation products, primarily 5'-AMP. This process is distinct from cAMP-mediated signaling (GO:0019933) and from cAMP biosynthetic process (GO:0006171). The primary enzymatic route is hydrolysis of the 3',5'-phosphodiester bond by cyclic nucleotide phosphodiesterases (PDEs), yielding 5'-AMP. The term is synonymous with cAMP breakdown, cAMP degradation, and cyclic AMP catabolism.
Why Is cAMP catabolic process Important in Cell Biology?
cAMP catabolic process is essential for resetting the cAMP signaling system after receptor activation, thereby preventing prolonged or inappropriate cellular responses. Because cAMP controls diverse processes such as cardiac contractility, neuronal plasticity, immune function, and hormone secretion, its timely degradation is critical for normal physiology. Dysregulation of cAMP breakdown is linked to a growing list of human diseases, including thyroid carcinoma, heart failure, and neurological disorders. Consequently, the enzymes and regulatory mechanisms of cAMP catabolism are major targets for drug discovery and for CRISPR-based functional genomics.
• Terminates cAMP signals to maintain signaling specificity and prevent cellular overstimulation.
• Shapes intracellular cAMP gradients and nanodomains that control localized responses.
• Regulates cardiac contractility and rhythm; PDE inhibition is used in heart failure and arrhythmia.
• Modulates insulin and glucagon secretion in pancreatic islets.
• Influences mitochondrial calcium handling and steroidogenesis in adrenocortical cells.
• Contributes to cancer progression; elevated PDE4C is a biomarker in thyroid carcinoma.
• Affects astroglial function and neuroinflammation, with implications for brain disorders.
• Provides targets for pharmacological inhibitors (e.g., PDE inhibitors) and CRISPR screens.
• Cross-talks with AMPK signaling to integrate energy status with cAMP levels.
• Is a model system for studying compartmentalized second-messenger signaling.
What Happens During cAMP catabolic process?
Substrate recognition and binding
In simple terms: The enzyme grabs cAMP and holds it in place.
Phosphodiesterases (PDEs) selectively bind cAMP through a conserved catalytic domain. The binding is highly specific, allowing PDEs to discriminate cAMP from cGMP, although some PDEs are dual-specific. The active site contains a metal ion (usually Zn2+ and/or Mg2+) that coordinates the phosphate group of cAMP, positioning it for hydrolysis. This step is the first committed step of cAMP catabolism.
Hydrolysis of the 3',5'-phosphodiester bond
In simple terms: The enzyme cuts the ring of cAMP, turning it into AMP.
Once bound, the PDE catalyzes the hydrolysis of the 3',5'-cyclic phosphate bond, converting cAMP to 5'-AMP. This reaction is exergonic and essentially irreversible under physiological conditions. The metal ions in the active site activate a water molecule that attacks the phosphorus atom, leading to bond cleavage. The product, 5'-AMP, is then available for further metabolism or can be re-phosphorylated to ADP/ATP.
Spatial compartmentalization of cAMP degradation
In simple terms: Different parts of the cell have their own cAMP-degrading enzymes.
PDEs are not uniformly distributed; they are targeted to specific subcellular compartments such as the plasma membrane, nucleus, mitochondria, and cytoskeleton. This localization creates local cAMP gradients and nanodomains, allowing cells to decode cAMP signals in a spatially restricted manner. For example, in cardiomyocytes, distinct PDEs regulate cAMP pools that control contraction and gene expression. In astrocytes, PDE activity shapes cAMP dynamics that influence neuronal communication.
Feedback regulation of cAMP catabolism
In simple terms: The process can speed up or slow down based on cellular needs.
PDE activity is regulated by various mechanisms, including phosphorylation by PKA and other kinases, binding to regulatory proteins, and changes in gene expression. For instance, PKA-mediated phosphorylation of certain PDEs can increase their activity, forming a negative feedback loop that terminates cAMP signals. Conversely, some PDEs are inhibited by cGMP, allowing cross-talk between cAMP and cGMP pathways. This dynamic regulation ensures that cAMP catabolism is tuned to the intensity and duration of receptor stimulation.
Integration with other signaling pathways
In simple terms: cAMP breakdown talks to other cellular signals.
cAMP catabolism intersects with calcium signaling, AMPK signaling, and mitochondrial metabolism. In mitochondria, cAMP degradation influences calcium uptake and energy production. In adrenocortical cells, mitochondrial cAMP and Ca2+ metabolism are tightly linked, affecting steroidogenesis. Additionally, AMPK, a sensor of cellular energy status, can modulate cAMP levels by regulating PDE expression or activity. These interactions highlight the broader physiological significance of cAMP catabolic process.
Key Genes Involved in GO:0006198 cAMP catabolic process
The following genes encode enzymes and regulators that directly participate in or control cAMP catabolic process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PDE1A | Calcium/calmodulin-dependent PDE; hydrolyzes cAMP and cGMP | Neuronal signaling, cardiovascular function |
| PDE1B | Calcium/calmodulin-dependent PDE; cAMP hydrolysis | Neurodegeneration, schizophrenia |
| PDE2A | cGMP-stimulated PDE; dual-specific for cAMP and cGMP | Adrenal steroidogenesis, heart failure |
| PDE3A | cGMP-inhibited PDE; major cAMP-hydrolyzing enzyme in heart and platelets | Cardiovascular disease, oocyte maturation |
| PDE3B | cGMP-inhibited PDE; regulates insulin secretion and lipolysis | Diabetes, obesity |
| PDE4A | cAMP-specific PDE; widely expressed | Inflammation, depression, memory |
| PDE4B | cAMP-specific PDE; regulates immune and neuronal functions | Asthma, COPD, neuroinflammation |
| PDE4C | cAMP-specific PDE; biomarker in thyroid carcinoma | Thyroid cancer diagnosis and prognosis |
| PDE4D | cAMP-specific PDE; long isoform regulates proliferation | Cancer, cardiovascular disease |
| PDE7A | High-affinity cAMP-specific PDE | T-cell activation, leukemia |
| PDE7B | cAMP-specific PDE; expressed in brain and pancreas | Neurological disorders, diabetes |
| PDE8A | cAMP-specific PDE; insensitive to rolipram | Steroidogenesis, cancer |
| PDE8B | cAMP-specific PDE; regulates aldosterone secretion | Hypertension, adrenal disorders |
| PDE10A | Dual-specific PDE; highly expressed in striatum | Huntington's disease, schizophrenia |
| PDE11A | Dual-specific PDE; expressed in prostate, testis | Prostate cancer, adrenal hyperplasia |
| PRKACA | Catalytic subunit of PKA; phosphorylates PDEs and other targets | Cushing's syndrome, cardiac disease |
| PRKAR1A | Regulatory subunit of PKA; modulates cAMP signaling | Carney complex, endocrine tumors |
| ADCY1 | Adenylyl cyclase; synthesizes cAMP (opposing catabolism) | Brain development, learning |
| ADCY5 | Adenylyl cyclase; synthesizes cAMP | Dyskinesia, diabetes |
How Is cAMP catabolic process Regulated?
cAMP catabolic process is regulated at multiple levels. Transcriptionally, PDE genes are induced or repressed by hormones and growth factors, altering the cell's capacity to degrade cAMP. Post-translationally, PDEs are phosphorylated by PKA and other kinases, which can either stimulate or inhibit their activity, creating feedback loops. Compartmentalization further regulates catabolism by localizing PDEs to specific subcellular sites, where they control local cAMP concentrations. Additionally, cGMP can modulate PDE activity; for example, cGMP inhibits PDE3, thereby reducing cAMP breakdown and elevating cAMP levels. Cross-talk with AMPK signaling also influences cAMP catabolism, as AMPK activation can affect PDE expression and activity. These regulatory mechanisms ensure that cAMP degradation is dynamically matched to cellular demands.
cAMP catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PDE4C | Thyroid carcinoma; poor survival | Knockout and overexpression in thyroid cancer cell lines |
| PDE3A | Heart failure; arrhythmia | Cardiomyocyte-specific knockout and point mutation models |
| PDE4B | Neuroinflammation; depression | Brain-specific knockout and knock-in mice |
| PDE8B | Hypertension; adrenal hyperplasia | Adrenal cell knockout and overexpression |
| PDE2A | Adrenal steroidogenesis; heart failure | Knockout and tagged knock-in in adrenocortical cells |
cAMP catabolism in cancer
Altered cAMP catabolism contributes to cancer development and progression. Elevated expression of PDE4C has been identified as a candidate diagnostic biomarker and is correlated with poor survival in thyroid carcinoma. Other PDEs, such as PDE4D and PDE8A, have been implicated in prostate and other cancers, where they may promote proliferation or survival. Targeting cAMP catabolism is therefore an emerging therapeutic strategy in oncology.
Cardiovascular and metabolic disorders
In the heart, cAMP catabolism by PDEs is critical for maintaining normal contractility and rhythm. Disruption of cAMP nanodomains, often due to altered PDE activity, is associated with heart failure and arrhythmias. In pancreatic islets, cAMP degradation regulates insulin and glucagon secretion, and dysregulation can contribute to diabetes. PDE inhibitors are used clinically for heart failure and are being explored for metabolic diseases.
Neurological and psychiatric conditions
cAMP catabolism in the brain affects neuronal plasticity, memory, and mood. Astroglial cAMP signaling, which is shaped by PDEs, influences neuroinflammation and neuronal excitability. Inhibitors of PDE4, a major cAMP-degrading enzyme in the brain, have been investigated for depression and cognitive disorders. Mitochondrial cAMP catabolism also impacts neuronal survival and function.
Mitochondrial and adrenal disorders
Mitochondrial cAMP catabolism is linked to calcium handling and steroidogenesis in adrenocortical cells. Dysregulation of this process can lead to adrenal insufficiency or hyperaldosteronism. Additionally, mitochondrial cAMP cross-talk with Ca2+ is important in cardiac and neuronal mitochondria, where perturbations may contribute to disease.
From cAMP catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PDE4C affect thyroid cancer cell proliferation? | PDE4C knockout in thyroid carcinoma cell lines |
| How does a point mutation in PDE3A alter cAMP hydrolysis? | CRISPR point mutation knock-in in cardiomyocytes |
| Can tagging endogenous PDE4B reveal its subcellular localization? | Tagged knock-in of PDE4B in astrocytes |
| What is the effect of PDE8B overexpression on aldosterone secretion? | Overexpression of PDE8B in adrenal cell lines |
| Which PDEs regulate insulin secretion? | CRISPR knockout of PDE isoforms in pancreatic beta cells |
| Does PDE4 inhibition mimic knockout in neurons? | Pharmacological inhibition and knockout in neuronal cultures |
How to Study the cAMP catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Live-cell cAMP imaging | Real-time cAMP concentration and localization | Study cAMP nanodomains in cardiomyocytes |
| PDE activity assay | Enzymatic hydrolysis rate of cAMP | Kinetic analysis of PDE mutants |
| CRISPR knockout screening | Genes affecting cAMP levels or cell fitness | Identify novel regulators of cAMP catabolism |
| Phosphoproteomics | Phosphorylation of PDEs and signaling proteins | Map PKA feedback on PDEs |
| Metabolomics | Levels of cAMP, AMP, adenosine | Assess flux through catabolic pathway |
| FRET-based biosensors | cAMP dynamics in live cells | Measure compartmentalized cAMP in astrocytes |
| RNA-seq | Transcriptional changes in PDE genes | Evaluate regulation of cAMP catabolism |
| Proximity ligation assay | Protein-protein interactions of PDEs | Detect PDE complexes in situ |
Live-cell cAMP imaging
Genetically encoded cAMP sensors (e.g., EPAC-based probes) allow real-time visualization of cAMP dynamics with high spatial and temporal resolution. These sensors can be targeted to specific subcellular compartments to study local cAMP catabolism. Imaging in cardiomyocytes and astrocytes has revealed cAMP nanodomains shaped by PDEs.
Phosphodiesterase activity assays
In vitro PDE activity assays using radiolabeled cAMP or fluorescent substrates measure the catalytic rate of cAMP hydrolysis. These assays are used to determine enzyme kinetics, inhibitor potency, and the impact of mutations. They can be performed on recombinant proteins or cell lysates.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout or activation screens can identify genes that regulate cAMP levels and catabolism. For example, screens in cancer cells can uncover PDEs or regulators that affect proliferation or drug response. These approaches are powerful for discovering novel components of cAMP catabolic process.
Phosphoproteomics and metabolomics
Mass spectrometry-based phosphoproteomics can quantify phosphorylation changes in PDEs and downstream targets upon modulation of cAMP catabolism. Metabolomics can measure cAMP and its degradation products (e.g., 5'-AMP, adenosine) to assess flux through the pathway. These methods provide systems-level insights.
How CRISPR Can Be Used to Study GO:0006198 cAMP catabolic process
Knockout
CRISPR knockout of PDE genes (e.g., PDE4C, PDE3A) eliminates enzyme activity, leading to elevated cAMP levels and altered downstream signaling. This approach is used to study the loss-of-function effects in cancer, cardiac, and neuronal cells. Knockout models can reveal whether a specific PDE is required for a given biological process.
Point Mutation
CRISPR point mutation knock-in can introduce specific amino acid substitutions in PDE catalytic domains to dissect their role in substrate binding or catalysis. For example, mutating the metal-coordinating residues can abolish activity, mimicking a catalytically dead enzyme. Such models help distinguish catalytic from non-catalytic functions.
Knock-in
Tagged knock-in of PDEs (e.g., with GFP or HA) allows visualization and immunoprecipitation of endogenous proteins. This is valuable for studying subcellular localization and interaction partners of PDEs in their native context. Knock-in of disease-associated mutations can also model human disorders.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can increase PDE levels, reducing cAMP and dampening signaling. Overexpression of PDE4C, for instance, has been used to study its role in thyroid carcinoma. This approach complements knockout studies by providing gain-of-function evidence.
How EDITGENE Supports cAMP catabolic process Research
Researchers studying cAMP catabolic process-related genes often need to determine whether a candidate gene is causally involved in a specific cellular phenotype, such as altered cAMP levels, proliferation, or survival. Establishing causality requires precise genetic manipulation, which can be achieved through CRISPR-based knockout, point mutation, knock-in, or overexpression models. EDITGENE provides end-to-end services to generate such models and to screen for related genes at scale.
Contact EDITGENE today to design your custom CRISPR model for cAMP catabolic process research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PDE4A Knockout HEK293 Cell Line | EDJ-KQ1828 | Human | 5141 | Details Get a Quote |
| PDE4B Knockout HEK293 Cell Line | EDJ-KQ1829 | Human | 5142 | Details Get a Quote |
| PDE4C Knockout HEK293 Cell Line | EDJ-KQ1830 | Human | 5143 | Details Get a Quote |
| PDE4D Knockout HEK293 Cell Line | EDJ-KQ1831 | Human | 5144 | Details Get a Quote |
| PDE10A Knockout HEK293 Cell Line | EDJ-KQ1832 | Human | 10846 | Details Get a Quote |
| PDE8A Knockout HEK293 Cell Line | EDJ-KQ5431 | Human | 5151 | Details Get a Quote |
| PDE7A Knockout HEK293 Cell Line | EDJ-KQ5433 | Human | 5150 | Details Get a Quote |
| PDE8B Knockout HEK293 Cell Line | EDJ-KQ6303 | Human | 8622 | Details Get a Quote |
| PDE7B Knockout HEK293 Cell Line | EDJ-KQ7947 | Human | 27115 | Details Get a Quote |
| PDE8B Knockout A-549 Cell Line | EDJ-KQ30209 | Human | 8622 | Details Get a Quote |
| PDE8B Knockout HeLa Cell Line | EDJ-KQ30210 | Human | 8622 | Details Get a Quote |
| PDE4B Knockout A-549 Cell Line | EDJ-KQ20367 | Human | 5142 | Details Get a Quote |
| PDE10A Knockout HeLa Cell Line | EDJ-KQ20374 | Human | 10846 | Details Get a Quote |
| PDE4A Knockout A-549 Cell Line | EDJ-KQ21680 | Human | 5141 | Details Get a Quote |
| PDE4A Knockout HCT 116 Cell Line | EDJ-KQ21681 | Human | 5141 | Details Get a Quote |
Displaying Records 1 To 15 Of 37 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About cAMP catabolic process
What is cAMP catabolic process?
cAMP catabolic process (GO:0006198) is the set of biochemical reactions that break down cyclic AMP (cAMP) into 5'-AMP, primarily through the action of phosphodiesterases.
What genes are involved in cAMP catabolic process?
Key genes include phosphodiesterases such as PDE1A, PDE2A, PDE3A, PDE4A-D, PDE7A/B, PDE8A/B, PDE10A, and PDE11A, as well as regulatory subunits like PRKAR1A.
How is cAMP degraded?
cAMP is degraded by cyclic nucleotide phosphodiesterases (PDEs), which hydrolyze the 3',5'-phosphodiester bond to produce 5'-AMP.
What is the role of PDE4C in cancer?
Elevated PDE4C level serves as a candidate diagnostic biomarker and correlates with poor survival in thyroid carcinoma.
Why is cAMP catabolism important in the heart?
In the heart, cAMP catabolism shapes local cAMP nanodomains that regulate contractility and rhythm; disruption is linked to heart failure and arrhythmias.
How does cAMP catabolism affect neurons?
Astroglial cAMP signaling, regulated by PDEs, influences neuronal excitability and neuroinflammation, with implications for brain disorders.
What methods are used to study cAMP catabolism?
Common methods include live-cell cAMP imaging, PDE activity assays, CRISPR screening, phosphoproteomics, and metabolomics.
Can CRISPR be used to study cAMP catabolic process?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise interrogation of PDE genes and their roles in cAMP catabolism.
What diseases are associated with defective cAMP catabolism?
Diseases include thyroid carcinoma, heart failure, diabetes, neurological disorders, and adrenal disorders.
How does cAMP catabolism cross-talk with other pathways?
cAMP catabolism intersects with calcium signaling, AMPK signaling, and mitochondrial metabolism, influencing diverse cellular functions.
Conclusion
cAMP catabolic process (GO:0006198) is a fundamental biological process that terminates cAMP signaling by hydrolyzing cAMP to 5'-AMP. The enzymes responsible, phosphodiesterases, are spatially and temporally regulated to shape cAMP gradients and nanodomains, which is critical for normal physiology and whose dysregulation contributes to cancer, cardiovascular, metabolic, and neurological diseases. Understanding this process offers therapeutic opportunities and requires advanced experimental models. CRISPR-based approaches, combined with imaging and omics methods, provide powerful tools to dissect the mechanisms and disease relevance of cAMP catabolism.
References
- 1. Aslam M et al.. 2022. Emerging Role of cAMP/AMPK Signaling.. Cells 11(2) PMID: 35053423
- 2. Wang Y et al.. 2024. Elevated PDE4C level serves as a candidate diagnostic biomarker and correlates with poor survival in thyroid carcinoma.. Sci Rep 14(1):6813 PMID: 38514754
- 3. Chao YC et al.. 2019. Imaging cAMP nanodomains in the heart.. Biochem Soc Trans 47(5):1383-1392 PMID: 31670375
- 4. Di Benedetto G et al.. 2014. Ca2+ and cAMP cross-talk in mitochondria.. J Physiol 592(2):305-12 PMID: 23858012
- 5. Horvat A et al.. 2019. Astroglial cAMP signalling in space and time.. Neurosci Lett 689:5-10 PMID: 29908259
- 6. Spät A et al.. 2018. Mitochondrial cAMP and Ca(2+) metabolism in adrenocortical cells.. Pflugers Arch 470(8):1141-1148 PMID: 29876637
- 7. Tengholm A et al.. 2017. cAMP signalling in insulin and glucagon secretion.. Diabetes Obes Metab 19 Suppl 1:42-53 PMID: 28466587
- 8. Robichaux WG 3rd et al.. 2018. Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.. Physiol Rev 98(2):919-1053 PMID: 29537337
